These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3688011)

  • 1. Effect of fenofibrate treatment on type III hyperlipoproteinemia.
    Fruchart JC; Davignon J; Bard JM; Grothe AM; Richard A; Fievet C
    Am J Med; 1987 Nov; 83(5B):71-4. PubMed ID: 3688011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
    Lussier-Cacan S; Bard JM; Boulet L; Nestruck AC; Grothé AM; Fruchart JC; Davignon J
    Atherosclerosis; 1989 Aug; 78(2-3):167-82. PubMed ID: 2783201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate affects the compositions of lipoproteins.
    Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
    Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
    Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM
    Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of estrogen therapy on apolipoprotein E in type II hyperlipoproteinemia.
    Falko JM; Schonfeld G; Witztum JL; Kolar J; Weidman SW
    Metabolism; 1979 Nov; 28(11):1171-7. PubMed ID: 226834
    [No Abstract]   [Full Text] [Related]  

  • 8. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Deshaies Y; Gagné C; Couture P
    Atherosclerosis; 2006 Sep; 188(1):203-12. PubMed ID: 16337207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate in type IV and type V hyperlipoproteinemia.
    Seidehamel RJ
    Cardiology; 1989; 76 Suppl 1():23-8; discussion 29-32. PubMed ID: 2653622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
    Cho EJ; Min YJ; Oh MS; Kwon JE; Kim JE; Kim CJ
    Am J Cardiol; 2011 Mar; 107(5):793-6. PubMed ID: 21247547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
    Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
    Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
    Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 20. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
    Schonfeld G; George PK; Miller J; Reilly P; Witztum J
    Metabolism; 1979 Oct; 28(10):1001-10. PubMed ID: 226830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.